1. Functional and phenotypic alterations in peritoneal macrophages from patients with early and advanced endometriosis
- Author
-
A. Raiter-Tenenbaum, Gabriela Fabiana Meresman, Rosa Ines Barañao, Lia S. Rumi, and J. J. Etchepareborda
- Subjects
Adult ,Infertility ,medicine.medical_specialty ,medicine.drug_class ,Population ,Endometriosis ,Dinoprostone ,Gonadotropin-Releasing Hormone ,Pathogenesis ,Phagocytosis ,Internal medicine ,Gonadotropin-releasing hormone agonist ,medicine ,Humans ,Prostaglandin E2 ,education ,Danazol ,education.field_of_study ,business.industry ,Macrophages ,Nitroblue Tetrazolium ,Estrogen Antagonists ,Obstetrics and Gynecology ,HLA-DR Antigens ,General Medicine ,Macrophage Activation ,medicine.disease ,Phenotype ,Endocrinology ,Female ,business ,Interleukin-1 ,medicine.drug ,Hormone - Abstract
The aim of this study was to elucidate whether peritoneal macrophage (pMO) alterations are a generalized feature in all stages of endometriosis and the effect of hormonal treatment on this leukocyte population. For this purpose we quantified the number of pMO, the expression of HLA-DR antigen (pMO DR+), percentages of pMO that reduced nitro-blue tetrazolium (pMO NBT+), and interleukin-1 (IL-1) and prostaglandin E2 (PGE2) production by pMO from patients with early (stages I/II) and advanced (stages III/IV) endometriosis, we also analyzed some of these properties in pMO from patients which had been treated for 6 months with 800 mg/day of Danazol or gonadotropin releasing hormone agonist (GnRHa). We found that there were a significant increase of the pMO number in both types of patients, though the highest values were obtained in early endometriosis (p
- Published
- 1998
- Full Text
- View/download PDF